7 replies to this topic

[cousineg]

These texts are extracted from a French article: http://www.romandie....535040AWPCH.asp

Novartis AG will face a change at  the expiry of the patent for Glivec in 2015/16.

Patients with chronic myeloid leukemia (CML), which are currently treated with Glivec, will have to adopt its successor, Tasigna

Novartis AG devra faire face à un changement à l'échéance du brevet de Glivec en 2015/16.

Les patients atteints de leucémie myéloïde chronique (LMC), qui sont traités actuellement avec Glivec, devront adopter son successeur, le Tasigna.

It is anticipated that 90% of all new patients with CML treated with Tasigna and  that 10-15% of patients  willl change from Gleevec to Tasigna.

Il est prévu que 90% de tous les nouveaux patients atteints de LMC soient traités avec Tasigna et que 10-15% des patients de Glivec changent pour Tasigna.

___________________________________________________________________________

Second-generation drugs called into first-line therapy for CML

February 25, 2011,  Hemonctoday

____________________________________________________________________________

Other news

Ce message a été modifié par: cousineg

[Sneezy12]

The comments do not make sense!

[PhilB]

The ones in French do, and he's done a much better job of translating the French to English than I could do the other way around !  (Although I don't know how the rogue 'caring' got in there)

[cousineg]

Sorry, there was a mistake in the French article.  Also, the Google translate made some mistakes too.

There is may be a confusion.  The sentence 'devront adopter le Tasigna'' means  'will have to adopt Tasigna'.

With this sentence,we can  interpret the text as if Novartis will completely stop the production of Glivec in 2015

But after, they said that 10-15% of patients  willl change from Gleevec to Tasigna.  There is a contradiction in the article. Novartis should not stop the production of Glivec in 2015 according to this second sentence.

[PhilB]

I was ignoring that bit as bad journalism.  The key part of the equation is that it won't matter that much if Novartis does stop production as there is at least one company already in the starting blocks to produce a generic the moment the patent expires.

[GerryL]

And in countries where our Glivec is heavily subsidized by the National Health System - we would more than likely be moved onto the Generic Glivec.

[cherylannes]

This is an article by Morgan Stanley, investment analysts.  The main purpose of which was to keep share holders happy.  It was released just prior to the ASH meeting where Novartis was going to present data from the ENEST II trial.  The results as we all know, show a favorable increase in disease knock down and better side effect profile.

So, this investment analyst is predicting that 90% of all newly diagnosed patients will go on Tasigna as front line, and 10-15% of patients currently on Gleevec will switch over to Tasigna.  The article also states that this is all necessary becasue the Gleevec patent will expire.  Which, I agree with GerryL, not only will patients in countries that have national healthcare programs have to go to the generic, but you can imagine that many insurance providers will insist that their patients switch to the generic as well.

However, the statement that says 90% of all patients will go on Tasigna is a very scary statement and I am not sure what the analyst is basing that on.  That sends a bad message to the other players in this market, to their shareholders.  We don't even know if 90% of the patient population can tolerate Tasigna.  According to IRIS, 30% of that patient population did not stay on Gleevec.  More competition is needed, we are not a one size fits all patient group, for all our similarities, we have many more differences.

We at the CML Society of Canada advocate "The right drug for the right patient at the right dose at the right time".  Doctors and patients must decide which treatment is best for them, not Wall Street....

Cheers!

[cherylannes]

This is an article by Morgan Stanley, investment analysts.  The main purpose of which was to keep share holders happy.  It was released just prior to the ASH meeting where Novartis was going ot present data from the ENEST II trial.  The results as we all know, show a fovorable increse in disease knock down and better side effect profile.

So, this investment analyst is predicting that 90% of all newly diagnosed patients will go on Tasigna as front line, and 10-15% of patients currently on Gleevec will switch over to Tasigna.  The article also states that this is all necessary becasue the Gleevec patent will expire.  Which, I agree with GerryL, not only will patients in countries that have national healthcare programs have to go to the generic, but you can imagine that many insurance providers will insist that their patients switch to the generic as well. 

However, the statement that says 90% of all patients will go on Tasigna is a very scary statement and I am not sure what the analyst is basing that on.  That sends a bad message to the other players in this market, to their shareholders.  We don't even know if 90% of the patient population can tolerate Tasigna.  According to IRIS, 30% of that patient population did not stay on Gleevec.  More competition is needed, we are not a one size fits all patient group, for all our similarities, we have many more differences.

We at the CML Society of Canada advocate "The right drug for the right patient at the right dose at the right time".  Doctors and patients must decide which treatment is best for them, not Wall Street....

Cheers!